Assessing usability of QIAreach QuantiFERON-TB platform in a high tuberculosis prevalence, low-resource setting

Conceptor Kaaba; Maria Ruperez; Barry Kosloff; Nduku Ndunda; Kwame Shanaube; Helen Ayles

doi:10.1183/23120541.00511-2021

Assessing usability of QIAreach QuantiFERON-TB platform in a high tuberculosis prevalence, low-resource setting

ERJ Open Res. 2021 Dec 27;7(4):00511-2021. doi: 10.1183/23120541.00511-2021. eCollection 2021 Oct.

Authors

Conceptor Kaaba¹, Maria Ruperez², Barry Kosloff^{1

2}, Nduku Ndunda³, Kwame Shanaube¹, Helen Ayles^{1

2}

Affiliations

¹ Zambart, Lusaka, Zambia.
² London School of Hygiene and Tropical Medicine, London, UK.
³ Cepheid Middle East, a Danaher company FZ LLC, Dubai, United Arab Emirates.

Abstract

QIAreach QuantiFERON-TB is a portable IGRA with the potential to improve accessibility of TB infection diagnosis in low-resource settings https://bit.ly/3nTzolf.